Biotech engineering bispecific antibodies and antibody-drug conjugates; zanidatamab targets HER2 cancers with Jazz Pharmaceuticals.
Biotech engineering bispecific antibodies and antibody-drug conjugates; zanidatamab targets HER2 cancers with Jazz Pharmaceuticals.
Has no product of its own on the market; income arrives as milestone payments and royalties when partners reach goals or sell drugs built on its technology. Jazz holds zanidatamab rights in most of the world outside Asia, where BeiGene holds them for parts of Asia-Pacific.
Moat: narrow (IP / patents, process know-how). Proprietary Azymetric bispecific-antibody platform is licensed to multiple large pharma partners.
Headquarters: Vancouver, Canada · Founded: 2003 · Employees: 264
Size Zymeworks (ZYME) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.81B, the 1838th largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.04 on 18 Nov 2026.
Performance Over six months the shares gained 4.8%, against -10.4% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 97.8% over the last twelve months (peer median +6.7%); the operating margin is 16.6% (peer median 10.0%).
Valuation It trades at 160.4× forward earnings against a peer median of 19.4× (most expensive of 19).
Capital Return on invested capital runs 5.7 points below its cost of capital (10.1% WACC).
Short interest Short interest is 8.4% of the free float (30 Oct 2026).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $266M | $106M | $76.3M | $76.0M | $412M |
| Revenue growth | — | +39% | 0% | -82% | — |
| Gross profit | $257M | $95.2M | $65.1M | $58.7M | $400M |
| EBITDA | $53.2M | -$81.8M | -$109M | -$121M | $143M |
| Net income | $43.3M | -$81.1M | -$123M | -$119M | $124M |
| Free cash flow | -$111M | -$34.5M | -$112M | -$121M | $136M |
| Capital expenditure | $985,872 | $2.35M | $3.07M | $4.08M | $13.1M |
| Total debt | $650M | $18.3M | $18.5M | $26.7M | $28.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zymeworks ZYME | $1.81B | +5% | +98% | 17% | 160.4× | n/a |
| Genmab A/S GMAB.CO | $30.8B | +103% | +15% | 31% | 40.9× | 11.6% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 18.1× | -0.1% |
| Daiichi Sankyo 4568.T | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% |
| Xencor XNCR | $2.58B | +204% | +34% | -73% | n/a | n/a |
| Sutro Biopharma STRO | n/a | -73% | n/a | n/a | n/a | n/a |
| Akeso 9926.HK | $7.01B | -48% | +42% | -25% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ZYME | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.2% | +0.7% | 8th lowest of 21 |
| 6-month return | +4.8% | -10.4% | 6th highest of 21 |
| Distance from 52-week high | -18.6% | -32.8% | 5th highest of 21 |
| Revenue growth (TTM) | +97.8% | +6.7% | 3rd highest of 21 |
| Operating margin | 16.6% | 10.0% | 10th highest of 21 |
| Forward P/E | 160.4× | 19.4× | most expensive of 19 |
| ROIC minus cost of capital | -5.7 pp | +2.4 pp | 7th lowest of 21 |
| EV / EBITDA | 44.4× | 19.8× | 2nd most expensive of 9 |
| Net debt / EBITDA | 10.3× | -0.7× | most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% | +0.5% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |